E-POSTER PRESENTATION
31st EADV CONGRESS
7-10 SEPTEMBER 2022
MILAN

4th International Conference on Cosmetology and Dermatology
November 7-8, 2022 Las Vegas, USA
cosmetology.euroscicon.com

Brodalumab seems to retrieve its therapeutic efficacy after a rather short "wash out" period with anti TNF agents. Is there a pattern?



Eleftheria Tampouratzi

Tzaneio General Hospital, Athens Greece

Abstact

Psoriasis is a lifelong disease with chronic relapsing course and treatment agents switching is a common accepted practice, in cases of primary or secondary inadequate response. Adalimumab and brodalumab, have been both demonstrated to be highly specific and efficient while sparing the cumulative toxicity observed by conventional antipsoriatic drugs use1,2. An observation study on 5 seriously suffering psoriatic patients, provided a rather successful pattern on double switching of the forementioned biologic agents. Therapy was firstly initiated with brodalumab and after secondary failure or occurrence of arthritic comorbidities, a short wash out period with adalimumab therapy followed without striking results. Read ministered brodalumab showed to retrieve the initial therapeutic efficacy on both skin and joints. Read ministered brodalumab showed to retrieve the initial therapeutic efficacy on both skin and joints. Switch therapy in patients with severe psoriasis is a common clinical practice, due to chronic unpredictable course of the disease, in nonresponsive or relapsing cases .The underlying mechanism for secondary loss of efficacy of a biologic agent is still obscured , possibly due to altered immunogenicity closely connected to complexed cytokine imbalance, and activation of secondary pathways in disease induction and /or exacerbation3,4,5 . The present study describes an unobserved (as far as is known) successful management of severe psoriasis when for some reason initially administered brodalumab, temporarily loses its effectiveness.It seems that the interference of another agent (adalimumab) for a more or less short period, enables the full healing capacity of the initial drug to be restored, with a positive rebound type therapeutic outcome. The observed model may be worth studying in a larger number of patients, perhaps enlightening the underlying mechanisms and offering a pattern for a more efficient approach in primary or secondary resistant cases.

Biography

Dr. Eleftheria Tampouratzi is a Consultant Dermatologist and Venereologist in Tzaneio General Hospital of Athens, in Greece. Graduated Medical School of Athens, where she is practicing her doctoral on "The contribution of vitamin C to the healing of dermatosurgical wounds in combination with silicone gel". She has attended EADV training courses : trichoscopy in Warsaw in 2015 and nail surgery in 2017 in Brussels. She has publications in journals including JAAD, Experimental Dermatology, Journal of Investigative Dermatology, Journal of Dermatological Treatment, Pediatric Dermatology and is active participant in Greek, European and American Dermatology Conferences with speeches,free announcements, e-posters. She participates in 9 research protocols in Tzaneio Hospital and in 3 phase III studies, on the subject of psoriasis and atopic dermatitis. She is member of the Hellenic Dermatology Society (EDAE), Hellenic Society of Dermatosurgery (HSDS), Scientific Society of Musculoskeletal Health (EPEMY), European Society of Dermatology Venereology (EADV), European Hidradenitis Suppurativa Society (EHSF).

Recent Publications

- 2018:Tampouratzi E, Platsidaki E, Grivas T, Katsantonis I "An unusual late onset of ichthyosis hystrix" Skinmed 2018 16(5):365-367
- 2019: Tampouratzi E, Kanni T, Kapizioni C, Douvali T, Katsantonis I"Resistant Atopic Dermatitis Successfully Treated with Omalizumab: Report of 2 Cases." J Dermatol Surg Res Ther 2019 2(2) : 81-83.
- 2019:Ioannidis D, Tampouratzi E, Platsidaki e, et al"165 Scalp, palmoplanar and nail involvement in moderate bio-naïve psoriasis patients treated with apremilast: 6-week interim results of a real-world, multicenter, prospective study in Greece" J Invest Dermatol 2019 139(9):242
- 2020:Tampouratzi E, Kanni T, Douvali T, Katsantonis I "Modified Mercedes flap- an effective reconstructive option for lower leg skin defects" Journal of Dermatological Treatment, 2020 31(6): 649-650
- 2020: Tampouratzi E, Kanni T, Katsantonis I, Douvali T" Psoriasis-COVID 19 Infection: Treatment options" Skinmed. 2020 Mar 1;18(2):81-82. eCollection 2020
- 2020:Tampouratzi E, Michalopoulos G, Koutoufaris G, Kanni T, Vrakas S "Rosacea and Helicobacter pylori, is there any Relationship?" Archives of Surgical Dermatology 2020 3(2):37-39
- 2020 : Ioannides D, Vryzaki E, Panagakis P, Tampouratzi E, et al. "13643 Improvement in specific locations, quality of life, and pruritus after 24 weeks of apremilast in bio-naïve moderate plaque psoriasis patients who failed to achieve a PASI-75 response: Interim results of a real-world prospective study in Greece (APRAISAL)" JAAD 83,6
- 2020 : Tampouratzi E, Kanni T, Katsantonis I, Douvali T " Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches" F1000Research 2020 8 (https://doi.org/10.12688/f1000research.21216.2)
- 2020 : Tampouratzi E, Katsantonis I "Certolizumab pegol or brodalumab as reliable therapeutic option for coexisting hidradenitis suppurativa with psoriasis" Experimental Dermatology 2020 29(Suppl 1) 5-66
- 2021 : Tampouratzi E, Katsantonis I "Is acne conglobate the opposite spectrum of hidradenitis suppurativa especially when it responds well to adalimumab?" Experimental Dermatology 2021 30(Suppl 1) 76
- 2021 : Douvali T, Emmanouil G, Gerochristou M, Gerodimou M, Tampouratzi E, et al "Co-existance of Parry Romberg syndrome and lichen sclerosus et atrophicus in an adolescent girl : a rare combination" Our Dermatology Online 2021 12(3):294-296
- 2021: Douvali T,Papageorgiou V, Gerochristou M, Gerodimou M, Tampouratzi , et al "Harlequin Syndrome in a young girl. A report of a case: Rethinking the definition of the term" Pediatric Dermatology 2021 38(4):984-985 (https:// doi.or/10.1111.pde.14681)
- 2021: Tampouratzi E, Kanni T, Katsantonis J, et al "Maculopapular cutaneous mastocytosis successfully treated with omalizumab" Acta Dermatovenereol Croat 2021 29(1):60-61
- 2021 : Ioannides D, Tampouratzi E, Rigopoulos D, et al "Quality of life and pruritus over 52 weeks of apremilast treatment in biologic-naive patients with moderate plaque psoriasis: Results of a real-world, multicenter, prospective study in Greece (APRAISAL)" JAAD 2021 85(3):AB150
- 2022: Ioannides D, Antonakopoulos N, Chasapi V, Oikonomou C, Tampouratzi E, et al prospective study of the effectiveness and safety of apremilast in bio-naïve adults with moderate plaque psoriasis treated in the routine care in Greece - The 'APRAISAL' study". JEADV 2022 Apr 22. doi: 10.1111/jdv.18166. Online ahead of print. PMID: 35451115
- 2022: Tampouratzi E, Papakonstantis M, Katsantonis J, et al "Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: experience from clinical practice of 4 tertiary hospitals" Dermatol Ther. 2022 Apr 21:e15532. doi: 10.1111/dth.15532. Online ahead of print.

References

1. 1. Lebwohl M, Menter A, Lain E, et al “Long-term skin clearance with brodalumab in patients with psoriasis and adequate response to prior biologics” J Drugs Dermatol 2022 21(3):364-370
2. 2. Shahwan KT, Kimball AB “Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy” Int J Womens Dermatol 2016 2:151-153
3. 3. Bagel J, Lebwohl M, Israel RJ “Imunogenicity and skin clearance recapture in clinical studies of brodalumab” JAAD 2020 82:344-351
4. 4. Menter A, Armstrong A, Van Voorhees A, et al “Brodalumab to the rescue: efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics” Dermato Ther (Heidelb) 2020 10:615-621
5. 5. Bhatia N, Alexis A, Anbalagan N, et al “A long term efficacy of brodalumab in patients with moderate to severe psoriasis who received prior biologics” poster presented at :Innovations in Dermatology Virtual Spring Conference: March